JP7495983B2 - Ｅｇｆｒ阻害剤 - Google Patents

Ｅｇｆｒ阻害剤 Download PDF

Info

Publication number
JP7495983B2
JP7495983B2 JP2022536419A JP2022536419A JP7495983B2 JP 7495983 B2 JP7495983 B2 JP 7495983B2 JP 2022536419 A JP2022536419 A JP 2022536419A JP 2022536419 A JP2022536419 A JP 2022536419A JP 7495983 B2 JP7495983 B2 JP 7495983B2
Authority
JP
Japan
Prior art keywords
group
alkyl group
compound
egfr
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022536419A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022014639A1 (https=
JPWO2022014639A5 (https=
Inventor
憩 小口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JPWO2022014639A1 publication Critical patent/JPWO2022014639A1/ja
Publication of JPWO2022014639A5 publication Critical patent/JPWO2022014639A5/ja
Application granted granted Critical
Publication of JP7495983B2 publication Critical patent/JP7495983B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022536419A 2020-07-15 2021-07-14 Ｅｇｆｒ阻害剤 Active JP7495983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020121525 2020-07-15
JP2020121525 2020-07-15
PCT/JP2021/026461 WO2022014639A1 (ja) 2020-07-15 2021-07-14 Ｅｇｆｒ阻害剤

Publications (3)

Publication Number Publication Date
JPWO2022014639A1 JPWO2022014639A1 (https=) 2022-01-20
JPWO2022014639A5 JPWO2022014639A5 (https=) 2023-03-27
JP7495983B2 true JP7495983B2 (ja) 2024-06-05

Family

ID=79554696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536419A Active JP7495983B2 (ja) 2020-07-15 2021-07-14 Ｅｇｆｒ阻害剤

Country Status (12)

Country Link
US (1) US20230285397A1 (https=)
EP (1) EP4197538A4 (https=)
JP (1) JP7495983B2 (https=)
KR (1) KR102873219B1 (https=)
CN (1) CN116368136B (https=)
AU (1) AU2021309779B2 (https=)
BR (1) BR112023000770A2 (https=)
CA (1) CA3189460A1 (https=)
MX (1) MX2023000693A (https=)
PH (1) PH12023550119A1 (https=)
TW (1) TW202216152A (https=)
WO (1) WO2022014639A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183395A4 (en) * 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
BR112023000765A2 (pt) * 2020-07-15 2023-02-07 Taiho Pharmaceutical Co Ltd Cristal de composto de pirimidina
EP4351737A4 (en) * 2021-05-24 2025-05-14 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
WO2020145374A1 (ja) 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
ES2775751T3 (es) * 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
WO2020145374A1 (ja) 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩
JP6783974B1 (ja) 2019-01-11 2020-11-11 大鵬薬品工業株式会社 ピリミジン化合物又はその塩

Also Published As

Publication number Publication date
JPWO2022014639A1 (https=) 2022-01-20
BR112023000770A2 (pt) 2023-02-07
EP4197538A1 (en) 2023-06-21
AU2021309779A1 (en) 2023-02-23
WO2022014639A1 (ja) 2022-01-20
US20230285397A1 (en) 2023-09-14
MX2023000693A (es) 2023-02-13
KR20230026451A (ko) 2023-02-24
CA3189460A1 (en) 2022-01-20
AU2021309779B2 (en) 2024-06-27
KR102873219B1 (ko) 2025-10-17
CN116368136A (zh) 2023-06-30
EP4197538A4 (en) 2024-08-07
TW202216152A (zh) 2022-05-01
PH12023550119A1 (en) 2024-06-24
CN116368136B (zh) 2025-09-05

Similar Documents

Publication Publication Date Title
JP7495983B2 (ja) Ｅｇｆｒ阻害剤
EP3909584B1 (en) Pyrimidine compound or salt thereof
KR20100132023A (ko) 아실티오우레아 화합물 또는 그 염 및 그 용도
KR101905295B1 (ko) 나프티리딘디온 유도체
JP7373664B2 (ja) 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
RU2817044C1 (ru) Ингибитор egfr
RU2787992C1 (ru) Пиримидиновое соединение или его соль
BR112021013460B1 (pt) Composto pirimidina, composição farmacêutica e agente antitumoral que compreendem o mesmo e usos do dito composto para o tratamento de tumor
BR122024008319A2 (pt) Composto pirimidina, composição farmacêutica e agente antitumoral que compreendem o mesmo e usos do dito composto para o tratamento de tumor
WO2022014638A1 (ja) ピリミジン化合物の結晶
HK40090490B (zh) Egfr抑制剂
HK40090490A (zh) Egfr抑制剂
RU2827100C1 (ru) Комбинация, содержащая пиримидиновое соединение, для применения в лечении опухолей
HK40056369B (zh) 嘧啶化合物或其盐
HK40056369A (en) Pyrimidine compound or salt thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240524

R150 Certificate of patent or registration of utility model

Ref document number: 7495983

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150